Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels
Loading...
Authors
Campagna, Noah
Date
Type
thesis
Language
eng
Keyword
hERG , remdesivir , lumacaftor , long QT syndrome , cardiac arrhythmia , whole-cell voltage patch-clamp , Western blot
Alternative Title
Abstract
The human ether-a-go-go-related gene (hERG) (KCNH2) encodes the pore-forming a-subunit of the channel (Kv11.1) that conducts the rapidly activating delayed potassium current (IKr) in the heart. The hERG channel is important for the repolarization phase of ventricular action potentials, and mutations causing reduction of its expression in the plasma membrane can result in long QT syndrome type 2 (LQT2). As such, promoting hERG membrane expression is a strategy to rescue mutant channel function. In this study, the rescue effects of two drugs, remdesivir and lumacaftor, on trafficking defective mutant hERG channels were studied by applying patch clamp, Western blot, immunocytochemistry, and Quantitative Reverse Transcription PCR techniques. As our lab has recently reported that the antiviral drug remdesivir, used to treat COVID-19, increases wild-type (WT) hERG current and surface expression, we studied the effects of remdesivir on trafficking defective LQT2-causing hERG mutants G601S and R582 in HEK293 cells. The effects of lumacaftor, a drug used to treat cystic fibrosis that promotes CFTR protein trafficking and has been shown to rescue membrane expression of some hERG mutations, were also investigated. These results show that neither remdesivir nor lumacaftor rescued the current or mature protein expression of homomeric mutant G601S. However, remdesivir decreased while lumacaftor increased the current and mature protein expression of heteromeric channels formed by WT hERG and mutant G601S or R582C. These results demonstrate that drugs can differentially affect homomeric WT and heteromeric mutant-containing hERG channels, extend our understanding of drug-channel interaction, and may have clinical implications for patients with hERG mutations. Remdesivir may exacerbate LQT2, while lumacaftor has potential to mitigate LQT2.
Description
Citation
Publisher
License
Queen's University's Thesis/Dissertation Non-Exclusive License for Deposit to QSpace and Library and Archives Canada
ProQuest PhD and Master's Theses International Dissemination Agreement
Intellectual Property Guidelines at Queen's University
Copying and Preserving Your Thesis
This publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.
ProQuest PhD and Master's Theses International Dissemination Agreement
Intellectual Property Guidelines at Queen's University
Copying and Preserving Your Thesis
This publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.